Knotus Co Ltd
KOSDAQ:278650
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 995
4 510
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Knotus Co Ltd
Additional Paid In Capital
Knotus Co Ltd
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Additional Paid In Capital
₩60.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Additional Paid In Capital
₩6.5T
|
CAGR 3-Years
38%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Additional Paid In Capital
₩225.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Additional Paid In Capital
₩120.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Additional Paid In Capital
₩97.5B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
11%
|
|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Additional Paid In Capital
₩170B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
Knotus Co Ltd
Glance View
KNOTUS Co. Ltd. engages in the provision of clinical research services. The company is headquartered in Incheon, Incheon. The company went IPO on 2019-11-27. is a Korea-based company principally engaged in the nonclinical experiment business. Along with subsidiaries, the Company operates its business through three segments. The Nonclinical Contract Research Organization (CRO) Business segment conducts nonclinical experiments on new developed substances such as new drugs, and tests the efficacy and pharmacodynamics of the substances. This segment also provides services including new drug development related equipment, software and analysis of experimental results. The Animal Laboratory Construction Business segment is engaged in the construction and design of animal laboratories and the supply of reagent consumables. The Pet Business segment is engaged in the development of animal medicines and the sale of pet supplies.
See Also
What is Knotus Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
60.1B
KRW
Based on the financial report for Dec 31, 2023, Knotus Co Ltd's Additional Paid In Capital amounts to 60.1B KRW.
What is Knotus Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
54%
Over the last year, the Additional Paid In Capital growth was 89%. The average annual Additional Paid In Capital growth rates for Knotus Co Ltd have been 28% over the past three years , 54% over the past five years .
You don't have any saved screeners yet
